Italia markets closed

TVTX Jun 2024 5.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,1000+0,2200 (+11,70%)
Alla chiusura: 03:54PM EDT
Schermo intero
Chiusura precedente1,8800
Aperto2,1000
Denaro1,8500
Domanda2,9500
Prezzo d'esercizio5,00
Scadenza2024-06-21
Min-Max giorno2,1000 - 2,1000
Contratto - Min-MaxN/D
Volume14
Open Interest141
  • GlobeNewswire

    Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

    Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for presentation highlight Travere’s leadership and commitment in the field of rare kidney disease SAN DIEGO, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including two late-breaking oral presentations, at the upcoming Ame

  • GlobeNewswire

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to nine new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 29,250 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan

  • GlobeNewswire

    Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

    SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential effect of FILSPARI® (sparsentan) as a first-line therapy in patients with newly diagnosed IgA nephropathy (IgAN) in a late-breaking trial session at the 17th International Symposium on IgA Nephropathy (IIGANN2023) in Ryogoku, Tokyo, September 28-30, 2023. The Company will al